ArticleApplied biochemistry and biotechnology2026
Therapeutic Potential of Heparin/Digoxin Encapsulated Polymeric Nanoparticles: Modulation of Arrhythmias and Neuroinflammation Using Low-Intensity Pulsed Ultrasound on in Vitro and in Vivo Efficacy.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventricular arrhythmias (VAs) are abnormal heart rhythms that primarily occur due to sympathetic overactivity (SOV). SOV can occur from microglia-mediated neuroinflammation. To overcome this, the non-invasive approach of Low-intensity pulsed ultrasound (LIPUS) modulating arrhythmias and neuroinflammation remains unclear. In this study, Heparin, an anticoagulant, and digoxin, a cardiac glycoside, are co-delivered via poly(ԑ-caprolactone) polymeric nanoparticles (Hep/Dx@PCL-NPs) to improve therapeutic efficacy and reduce systemic side effects. In vitro biocompatibility of Hep/Dx@PCL-NPs retains the viability of cells and reduces the apoptosis rate in H9C2 myocardial cells. In an in vivo study, rats were randomly assigned to four groups: Control, Control + LIPUS, Hep/Dx@PCL-NPs, and Hep/Dx@PCL-NPs + LIPUS. Cardiac dysfunction was induced via coronary artery ligation surgery, and the vulnerability of VAs was assessed through electrophysiological studies. Heart rate variability (HRV) and left stellate ganglion (LSG) neural activity were utilized to assess sympathetic nerve activity. LIPUS significantly reduced fibrosis, dysfunction, and hypertrophy compared to the control group. Likewise, LIPUS therapy drastically lowered VA vulnerability and restored gap junction remodeling. The anti-arrhythmic effects of Hep/Dx@PCL-NPs + LIPUS decreased the P2 × 7/NLRP3 pathway, which in turn reduced microglial activation, neuroinflammation, SOV, and ventricular proinflammatory cytokine releases. This finding emphasizes the efficacy of Hep/Dx@PCL-NPs + LIPUS treatment in modulating antiarrhythmic effects.
Indexed as
Identifiers
41706404What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.